Details of the Drug

General Information of Drug (ID: DMK0O7U)

Drug Name
Flutamide
Synonyms
Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 276.21
Logarithm of the Partition Coefficient (xlogp) 3.3
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption
The drug is rapidly and completely absorbed []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [3]
Elimination
0.5% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 6 hours [4]
Metabolism
The drug is metabolized via plasma []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 38.79 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0095 mg/mL [2]
Chemical Identifiers
Formula
C11H11F3N2O3
IUPAC Name
2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
Canonical SMILES
CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
InChI
InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
InChIKey
MKXKFYHWDHIYRV-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3397
ChEBI ID
CHEBI:5132
CAS Number
13311-84-7
DrugBank ID
DB00499
TTD ID
D0Y0SW
VARIDT ID
DR00846
INTEDE ID
DR0733
ACDINA ID
D00288
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Antagonist [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [9]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [8]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [8]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
3-oxo-5-alpha-steroid 4-dehydrogenase 2 (SRD5A2) OTTG0NFD S5A2_HUMAN Gene/Protein Processing [11]
Advanced glycosylation end product-specific receptor (AGER) OTPY0IH7 RAGE_HUMAN Gene/Protein Processing [12]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Gene/Protein Processing [13]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Gene/Protein Processing [14]
Arylacetamide deacetylase (AADAC) OT8VACT2 AAAD_HUMAN Biotransformations [15]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [16]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Gene/Protein Processing [14]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Protein Interaction/Cellular Processes [17]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Gene/Protein Processing [14]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Gene/Protein Processing [18]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Prostate cancer
ICD Disease Classification 2C82.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Androgen receptor (AR) DTT AR 2.13E-01 -0.07 -0.11
Multidrug resistance-associated protein 1 (ABCC1) DTP MRP1 1.51E-01 -3.44E-01 -4.04E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 4.39E-01 -4.78E-02 -2.19E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 1.88E-01 -2.98E-02 -1.92E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.00E-03 1.34E-01 1.10E+00
Cytochrome P450 1B1 (CYP1B1) DME CYP1B1 2.23E-02 5.29E-01 4.59E-01
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 2.71E-02 -2.19E-01 -1.44E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 7.93E-02 -8.20E-02 -8.93E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Flutamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Flutamide and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [19]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Flutamide and Ivosidenib. Acute myeloid leukaemia [2A60] [20]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Flutamide and Midostaurin. Acute myeloid leukaemia [2A60] [21]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Flutamide and Idarubicin. Acute myeloid leukaemia [2A60] [21]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Flutamide and Daunorubicin. Acute myeloid leukaemia [2A60] [21]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Flutamide and Oliceridine. Acute pain [MG31] [21]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Flutamide and Metronidazole. Amoebiasis [1A36] [19]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Flutamide and Ivabradine. Angina pectoris [BA40] [21]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Flutamide and Bepridil. Angina pectoris [BA40] [22]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Flutamide and Dronedarone. Angina pectoris [BA40] [22]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Flutamide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [23]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [21]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Flutamide and Cilostazol. Arterial occlusive disease [BD40] [21]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Flutamide and Voriconazole. Aspergillosis [1F20] [21]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Flutamide and Posaconazole. Aspergillosis [1F20] [21]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Flutamide and Levalbuterol. Asthma [CA23] [24]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Terbutaline. Asthma [CA23] [25]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Pirbuterol. Asthma [CA23] [25]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Flutamide and Salbutamol. Asthma [CA23] [24]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Flutamide and Formoterol. Asthma [CA23] [25]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [21]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Flutamide and Desipramine. Attention deficit hyperactivity disorder [6A05] [21]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Flutamide caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [26]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Ofloxacin. Bacterial infection [1A00-1C4Z] [21]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [21]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Flutamide and Clarithromycin. Bacterial infection [1A00-1C4Z] [21]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Flutamide and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [22]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Flutamide and Sparfloxacin. Bacterial infection [1A00-1C4Z] [27]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Flutamide and Gemifloxacin. Bacterial infection [1A00-1C4Z] [21]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Norfloxacin. Bacterial infection [1A00-1C4Z] [21]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Flutamide and Levofloxacin. Bacterial infection [1A00-1C4Z] [21]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Flutamide and Lomefloxacin. Bacterial infection [1A00-1C4Z] [21]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Flutamide and Telithromycin. Bacterial infection [1A00-1C4Z] [21]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Flutamide and Retigabine. Behcet disease [4A62] [21]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Flutamide and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [28]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Loperamide. Bowel habit change [ME05] [29]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Flutamide and Eribulin. Breast cancer [2C60-2C6Y] [21]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Flutamide and Tamoxifen. Breast cancer [2C60-2C6Y] [21]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Flutamide and Toremifene. Breast cancer [2C60-2C6Y] [22]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Flutamide and Bosutinib. Breast cancer [2C60-2C6Y] [21]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Flutamide and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [21]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Olodaterol. Chronic obstructive pulmonary disease [CA22] [25]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Flutamide and Vilanterol. Chronic obstructive pulmonary disease [CA22] [24]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Salmeterol. Chronic obstructive pulmonary disease [CA22] [25]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Flutamide and Indacaterol. Chronic obstructive pulmonary disease [CA22] [25]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Flutamide and Arformoterol. Chronic obstructive pulmonary disease [CA22] [25]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Flutamide and Anisindione. Coagulation defect [3B10] [30]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Flutamide and Oxaliplatin. Colorectal cancer [2B91] [21]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Flutamide and Isoproterenol. Conduction disorder [BC63] [24]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Halothane. Corneal disease [9A76-9A78] [21]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Flutamide and Propofol. Corneal disease [9A76-9A78] [31]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Sevoflurane. Corneal disease [9A76-9A78] [21]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Flutamide and Probucol. Coronary atherosclerosis [BA80] [21]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Flutamide and Clofazimine. Crohn disease [DD70] [21]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Flutamide and Mifepristone. Cushing syndrome [5A70] [22]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Flutamide and Pasireotide. Cushing syndrome [5A70] [22]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Flutamide and Osilodrostat. Cushing syndrome [5A70] [21]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Flutamide and Sertraline. Depression [6A70-6A7Z] [21]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Flutamide and Trimipramine. Depression [6A70-6A7Z] [21]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Flutamide and Nortriptyline. Depression [6A70-6A7Z] [21]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Flutamide and Escitalopram. Depression [6A70-6A7Z] [22]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Flutamide and Clomipramine. Depression [6A70-6A7Z] [21]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Flutamide and Trazodone. Depression [6A70-6A7Z] [21]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Flutamide and Amoxapine. Depression [6A70-6A7Z] [21]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Flutamide and Doxepin. Depression [6A70-6A7Z] [21]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Flutamide and Maprotiline. Depression [6A70-6A7Z] [21]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Flutamide and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [21]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Flutamide and Deutetrabenazine. Dystonic disorder [8A02] [21]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Flutamide and Ingrezza. Dystonic disorder [8A02] [21]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Flutamide and Cannabidiol. Epileptic encephalopathy [8A62] [21]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Flutamide and Solifenacin. Functional bladder disorder [GC50] [21]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Flutamide and Pentamidine. Fungal infection [1F29-1F2F] [21]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Flutamide and Ketoconazole. Fungal infection [1F29-1F2F] [21]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Flutamide and Cisapride. Gastro-oesophageal reflux disease [DA22] [22]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Flutamide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [21]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Flutamide and Brentuximab vedotin. Hodgkin lymphoma [2B30] [32]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Flutamide and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [21]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Flutamide and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [33]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Flutamide and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [34]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Flutamide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [21]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Flutamide and Mipomersen. Hyper-lipoproteinaemia [5C80] [35]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Flutamide and Teriflunomide. Hyper-lipoproteinaemia [5C80] [22]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Flutamide and BMS-201038. Hyper-lipoproteinaemia [5C80] [36]
Givosiran DM5PFIJ Moderate Decreased metabolism of Flutamide caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [37]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Flutamide and Polyethylene glycol. Irritable bowel syndrome [DD91] [21]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Flutamide and Phenolphthalein. Irritable bowel syndrome [DD91] [22]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Flutamide and Methotrexate. Leukaemia [2A60-2B33] [21]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Flutamide and Porfimer Sodium. Lung cancer [2C25] [38]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Flutamide and Osimertinib. Lung cancer [2C25] [39]
Capmatinib DMYCXKL Moderate Decreased metabolism of Flutamide caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [40]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Flutamide and Selpercatinib. Lung cancer [2C25] [21]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Flutamide and Lumefantrine. Malaria [1F40-1F45] [19]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Flutamide and Halofantrine. Malaria [1F40-1F45] [41]
Chloroquine DMSI5CB Moderate Increased risk of prolong QT interval by the combination of Flutamide and Chloroquine. Malaria [1F40-1F45] [21]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Flutamide and Primaquine. Malaria [1F40-1F45] [21]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [21]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Flutamide and Idelalisib. Mature B-cell leukaemia [2A82] [42]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Flutamide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [43]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Flutamide and Clofarabine. Mature B-cell lymphoma [2A85] [44]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Flutamide and Vemurafenib. Melanoma [2C30] [22]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Flutamide and LGX818. Melanoma [2C30] [21]
Exjade DMHPRWG Moderate Decreased metabolism of Flutamide caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [45]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Flutamide and Thalidomide. Multiple myeloma [2A83] [19]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Flutamide and Siponimod. Multiple sclerosis [8A40] [19]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Flutamide and Fingolimod. Multiple sclerosis [8A40] [22]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Flutamide and Ozanimod. Multiple sclerosis [8A40] [46]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Flutamide and Romidepsin. Mycosis fungoides [2B01] [21]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Flutamide and Dasatinib. Myeloproliferative neoplasm [2A20] [21]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Flutamide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [47]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Flutamide and Promethazine. Nausea/vomiting [MD90] [21]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Granisetron. Nausea/vomiting [MD90] [21]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Flutamide and Dolasetron. Nausea/vomiting [MD90] [22]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Flutamide and Ondansetron. Nausea/vomiting [MD90] [21]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Flutamide and Entrectinib. Non-small cell lung cancer [2C25] [21]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Flutamide and Levomethadyl Acetate. Opioid use disorder [6C43] [21]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Lofexidine. Opioid use disorder [6C43] [21]
Olaparib DM8QB1D Moderate Increased metabolism of Flutamide caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [19]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Flutamide and Dextropropoxyphene. Pain [MG30-MG3Z] [21]
Prilocaine DMI7DZ2 Major Increased risk of methemoglobinemia by the combination of Flutamide and Prilocaine. Pain [MG30-MG3Z] [48]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Flutamide and Buprenorphine. Pain [MG30-MG3Z] [21]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Flutamide and Triclabendazole. Parasitic worm infestation [1F90] [21]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Flutamide and Pimavanserin. Parkinsonism [8A00] [21]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Flutamide and Apomorphine. Parkinsonism [8A00] [21]
Abametapir DM2RX0I Moderate Decreased metabolism of Flutamide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [49]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Flutamide and Famotidine. Peptic ulcer [DA61] [19]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Flutamide and Macimorelin. Pituitary gland disorder [5A60-5A61] [50]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Flutamide and Lefamulin. Pneumonia [CA40] [51]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Flutamide and Ritodrine. Preterm labour/delivery [JB00] [25]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Flutamide and Levomepromazine. Psychotic disorder [6A20-6A25] [21]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Flutamide and Fluphenazine. Psychotic disorder [6A20-6A25] [21]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Flutamide and Triflupromazine. Psychotic disorder [6A20-6A25] [21]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Flutamide and Gatifloxacin. Respiratory infection [CA07-CA4Z] [52]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Flutamide and Leflunomide. Rheumatoid arthritis [FA20] [22]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Flutamide and Quetiapine. Schizophrenia [6A20] [21]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Flutamide and Mesoridazine. Schizophrenia [6A20] [22]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Flutamide and Thioridazine. Schizophrenia [6A20] [22]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Flutamide and Aripiprazole. Schizophrenia [6A20] [19]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Flutamide and Iloperidone. Schizophrenia [6A20] [22]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Flutamide and Paliperidone. Schizophrenia [6A20] [21]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Flutamide and Haloperidol. Schizophrenia [6A20] [22]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Flutamide and Perphenazine. Schizophrenia [6A20] [21]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Flutamide and Trifluoperazine. Schizophrenia [6A20] [21]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Flutamide and Risperidone. Schizophrenia [6A20] [21]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Flutamide and Amisulpride. Schizophrenia [6A20] [53]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Asenapine. Schizophrenia [6A20] [21]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Flutamide and Pimozide. Schizophrenia [6A20] [21]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Vardenafil. Sexual dysfunction [HA00-HA01] [21]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Flutamide and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [21]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Flutamide and LEE011. Solid tumour/cancer [2A00-2F9Z] [22]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Flutamide and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [21]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Flutamide and Pitolisant. Somnolence [MG42] [21]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Flutamide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [21]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Flutamide and Naltrexone. Substance abuse [6C40] [54]
Warfarin DMJYCVW Moderate Increased risk of bleeding by the combination of Flutamide and Warfarin. Supraventricular tachyarrhythmia [BC81] [30]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Flutamide and Adenosine. Supraventricular tachyarrhythmia [BC81] [22]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Lenvatinib. Thyroid cancer [2D10] [21]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Flutamide and Cabozantinib. Thyroid cancer [2D10] [21]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Flutamide and Papaverine. Tonus and reflex abnormality [MB47] [55]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Flutamide and Tizanidine. Tonus and reflex abnormality [MB47] [21]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Flutamide and Tacrolimus. Transplant rejection [NE84] [21]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Flutamide and Astemizole. Vasomotor/allergic rhinitis [CA08] [21]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Flutamide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [21]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Flutamide and Procainamide. Ventricular tachyarrhythmia [BC71] [22]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Flutamide and Propafenone. Ventricular tachyarrhythmia [BC71] [21]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Flutamide and Flecainide. Ventricular tachyarrhythmia [BC71] [21]
⏷ Show the Full List of 165 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Flutamide 125 mg capsule 125 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6943).
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
7 The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett. 2003 Apr 30;142(1-2):61-70.
8 Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
9 Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
10 Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1298-303.
11 Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells. Toxicol In Vitro. 2007 Apr;21(3):502-8.
12 Prediction of drug-induced liver injury using keratinocytes. J Appl Toxicol. 2017 Jul;37(7):863-872. doi: 10.1002/jat.3435. Epub 2017 Jan 31.
13 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
14 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
15 Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Drug Metab Dispos. 2012 Apr;40(4):671-9. doi: 10.1124/dmd.111.043067. Epub 2011 Dec 29.
16 PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
17 Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations. Chem Biol Interact. 2011 Feb 1;189(3):177-85. doi: 10.1016/j.cbi.2010.11.008. Epub 2010 Nov 25.
18 Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
19 Cerner Multum, Inc. "Australian Product Information.".
20 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
21 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22 Canadian Pharmacists Association.
23 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
24 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
25 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
26 Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
27 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
28 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
29 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
30 Product Information. Eulexin (flutamide). Schering Laboratories, Kenilworth, NJ.
31 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
32 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
33 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
34 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
35 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
36 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
37 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
38 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
39 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
40 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
41 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
42 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
43 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
44 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
45 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
46 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
47 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
48 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
49 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
50 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
51 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
52 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
53 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
54 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
55 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]